Patents Assigned to Cothera BioScience, Inc.
  • Patent number: 12076399
    Abstract: Provided are combination therapies and related compositions and methods for treating cancers, including epithelial tumors, which include a combination of at least two agents such as an epidermal growth factor receptor (EGFR) inhibitor, a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and a cyclin dependent kinase (CDK) 4/6 inhibitor.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: September 3, 2024
    Assignee: Cothera Bioscience, Inc.
    Inventors: Yihong Zhang, Wang Wei, Yiyou Chen
  • Patent number: 12043630
    Abstract: The present disclosure provides crystalline polymorphic forms of TG02 free base and TG02 acid addition salts, pharmaceutical compositions comprising crystalline polymorphic forms of TG02 free base and TG02 acid addition salts, and methods of treating cancer and other diseases in a patient with crystalline polymorphic forms of TG02 free base and TG02 acid addition salts.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: July 23, 2024
    Assignee: Cothera Bioscience, Inc.
    Inventors: Robert K. Mansfield, Tracy Parrott
  • Patent number: 11753476
    Abstract: The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: September 12, 2023
    Assignee: Cothera BioScience, Inc.
    Inventors: Yiyou Chen, Chun Jiang
  • Publication number: 20210179718
    Abstract: The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Application
    Filed: April 8, 2019
    Publication date: June 17, 2021
    Applicant: Cothera BioScience, Inc.
    Inventors: Yiyou CHEN, Chun JIANG